ARTICLE | Company News
atugen genomics deal with AZN
October 16, 2001 7:00 AM UTC
atugen (Berlin, Germany) will develop its GeneBloc antisense platform to inhibit expression of gene targets selected by AstraZeneca (AZN) for target validation and therapeutic development in several i...